{"product_id":"recombinant-human-epo-protein-bhp22200011","title":"Recombinant Human EPO Protein","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}.bhp-desc .bhp-app-wrap{overflow-x:auto}.bhp-desc .bhp-app-table{width:100%;border-collapse:collapse;margin:12px 0 18px;font-size:14px}.bhp-desc .bhp-app-table th{background:#e8f0fb;color:#003366;text-align:left;padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-app-table td{padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\u003c\/style\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eRecombinant Protein · Glycoprotein Hormone\u003c\/span\u003e\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eRecombinant Human EPO Protein\u003c\/strong\u003e (erythropoietin) is expressed in \u003cstrong\u003ehuman cells\u003c\/strong\u003e and supplied as a glycosylated monomer. It is tag-free, animal-free and xeno-free, and is lyophilized from a 0.2 µm-filtered PBS solution without carrier protein, with purity \u0026gt;95% by SDS-PAGE and endotoxin \u0026lt;0.5 EU\/µg.\u003c\/p\u003e\n\u003cp\u003eEPO is used to support survival and maturation of EPOR-responsive erythroid progenitors, to study stage-specific erythroid commitment from CD34+ or pluripotent-cell-derived progenitors, to measure JAK2\/STAT5, PI3K–AKT and MAPK responses, and in TF-1 proliferation and comparative potency assays. Expression in human cells supports mammalian glycosylation of the protein.\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eExpression system: Human cells · Tag-free · Animal-free\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eErythropoietin is a glycoprotein hormone made mainly by the kidney when oxygen is low. On erythroid progenitors it binds the erythropoietin receptor (EPOR); downstream of EPOR\/JAK2, the STAT5, PI3K–AKT and MAPK pathways promote cell survival, proliferation and differentiation.\u003c\/p\u003e\n\u003cp\u003eEPO acts mainly on committed erythroid progenitors, especially CFU-E and early erythroblasts, while SCF and other signals act at earlier stages. In the laboratory it is used to study erythropoiesis, erythroid progenitor biology, hemoglobinization and EPOR signaling.\u003c\/p\u003e\n\u003ch2\u003eResearch Applications\u003c\/h2\u003e\n\u003cp\u003eEPO is used mainly at committed erythroid stages and in EPOR signaling and potency assays. The table shows typical placements; it is a planning guide, not a universal protocol.\u003c\/p\u003e\n\u003cdiv class=\"bhp-app-wrap\"\u003e\u003ctable class=\"bhp-app-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRole of EPO\u003c\/th\u003e\n\u003cth\u003eCompanion context\u003c\/th\u003e\n\u003cth\u003eSuggested readouts\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCD34+ erythroid differentiation\u003c\/td\u003e\n\u003ctd\u003eSupport of committed erythroid stages\u003c\/td\u003e\n\u003ctd\u003eSCF and stage-specific cytokine withdrawal\u003c\/td\u003e\n\u003ctd\u003eCD71, glycophorin A, hemoglobinization and enucleation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ehPSC-derived erythropoiesis\u003c\/td\u003e\n\u003ctd\u003eStage-specific erythroid maturation\u003c\/td\u003e\n\u003ctd\u003eMesoderm and hematopoietic induction factors at earlier stages\u003c\/td\u003e\n\u003ctd\u003eCD43, CD45, CD235a, globin expression\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPOR signaling assay\u003c\/td\u003e\n\u003ctd\u003eAcute receptor activation\u003c\/td\u003e\n\u003ctd\u003eSerum-reduced conditions and time course\u003c\/td\u003e\n\u003ctd\u003epJAK2, pSTAT5, pAKT and target genes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTF-1 potency assay\u003c\/td\u003e\n\u003ctd\u003eDose-dependent proliferation\u003c\/td\u003e\n\u003ctd\u003eDefined assay medium\u003c\/td\u003e\n\u003ctd\u003eProliferation, viability and relative potency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003ePlanning considerations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDefine the responsive cell stage and confirm EPOR expression or pathway competence.\u003c\/li\u003e\n\u003cli\u003eBegin with conditions from a validated protocol and titrate EPO in the actual cells, medium and endpoint; no numerical EC50 or universal working concentration is given for this product.\u003c\/li\u003e\n\u003cli\u003eControl timing and companion factors such as SCF, IL-3 and TPO, since signal order and duration can change lineage or functional outcomes.\u003c\/li\u003e\n\u003cli\u003eInclude no-factor, vehicle and pathway-response controls, and measure phenotype and function rather than cell number alone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eProtein Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlternative names\u003c\/th\u003e\n\u003ctd\u003eErythropoietin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecies\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression system\u003c\/th\u003e\n\u003ctd\u003eHuman cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStructure\u003c\/th\u003e\n\u003ctd\u003eGlycosylated monomer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eProtein family\u003c\/th\u003e\n\u003ctd\u003eGlycoprotein hormone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003ctd\u003eTag-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAnimal origin\u003c\/th\u003e\n\u003ctd\u003eAnimal-free \/ Xeno-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular weight\u003c\/th\u003e\n\u003ctd\u003e36 kDa. Refer to the lot-specific Certificate of Analysis (CoA) for lot data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e\u0026gt;95% by SDS-PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eEndotoxin level\u003c\/th\u003e\n\u003ctd\u003e\u0026lt;0.5 EU\/µg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eLyophilized from a 0.2 µm-filtered solution in PBS without carrier protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBiological activity\u003c\/th\u003e\n\u003ctd\u003eStimulation of human TF-1 cell proliferation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eApplications\u003c\/th\u003e\n\u003ctd\u003eStem Cell Differentiation, Immunotherapy, Hematopoietic Differentiation, Cell Proliferation, Cell Signaling Studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eBiological Activity \u0026amp; Quality Control\u003c\/h2\u003e\n\u003cp\u003eBiological activity is measured by stimulation of human TF-1 cell proliferation, with a concentration-dependent response.\u003c\/p\u003e\n\u003cp\u003eLot-specific activity and purity data are provided on the Certificate of Analysis (CoA), available from BioHippo on request.\u003c\/p\u003e\n\u003ch2\u003eReconstitution\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eBriefly centrifuge the vial before opening.\u003c\/li\u003e\n\u003cli\u003eReconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.\u003c\/li\u003e\n\u003cli\u003eMix gently and prepare aliquots.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eStorage \u0026amp; Shipping\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eAs supplied: −20°C to −80°C for up to 12 months from receipt. After reconstitution: 2°C to 8°C for up to 1 month, or −20°C to −80°C for up to 3 months, under sterile conditions. Avoid repeated freeze–thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003ePlease contact us to confirm shipping conditions for this product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eSelected References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eJelkmann W, et al. (2007) Erythropoietin after a century of research: younger than ever. Eur J Haematol 78:183-205. \u003ca href=\"https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00818.x\" target=\"_blank\" rel=\"noopener\"\u003e10.1111\/j.1600-0609.2007.00818.x\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eXavier-Ferrucio J, et al. (2018) Concise Review: Bipotent Megakaryocytic-Erythroid Progenitors: Concepts and Controversies. Stem Cells 36:1138-1145. \u003ca href=\"https:\/\/doi.org\/10.1002\/stem.2834\" target=\"_blank\" rel=\"noopener\"\u003e10.1002\/stem.2834\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eDulmovits BM, et al. (2017) Characterization, regulation, and targeting of erythroid progenitors in normal and disordered human erythropoiesis. Curr Opin Hematol 24:159-166. \u003ca href=\"https:\/\/doi.org\/10.1097\/MOH.0000000000000328\" target=\"_blank\" rel=\"noopener\"\u003e10.1097\/MOH.0000000000000328\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\u003cp style=\"margin:0\"\u003eHandle as a laboratory reagent and consult the linked SDS before use. Avoid repeated freeze–thaw cycles of the reconstituted protein.\u003c\/p\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cem\u003eFor research use only. Not for diagnostic or therapeutic use.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"StemImmune LLC","offers":[{"title":"10 ug","offer_id":67641419268461,"sku":"HHM-EP-0010","price":166.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":67641427165549,"sku":"HHM-EP-0100","price":948.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/EPO-500x500.png?v=1791572768","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-epo-protein-bhp22200011","provider":"BioHippo","version":"1.0","type":"link"}